

Amendments to Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims:

Claims 1-20 (Canceled).

21. (New) A method for treating dementia or one or more cognitive impairments caused by Parkinson's disease in a patient in need thereof comprising orally administering 5 milligrams to 10 milligrams of donepezil or a pharmaceutically acceptable salt thereof.


22. (New) The method of claim 21, wherein the donepezil or the pharmaceutically acceptable salt thereof is donepezil hydrochloride.

23. (New) The method of claim 21, wherein the donepezil is a stereoisomer of formula VII:



VII.

24. (New) The method of claim 21, wherein the donepezil is a stereoisomer of formula VIII:




VIII.

25. (New) The method of claim 21, comprising orally administering 5 milligrams to 10 milligrams of donepezil or a pharmaceutically acceptable salt thereof in the form of a tablet.

26. (New) A method for treating dementia or one or more cognitive impairments caused by Parkinson's disease in a patient in need thereof comprising administering a therapeutically effective amount of donepezil or a pharmaceutically acceptable salt thereof.


27. (New) The method of claim 26, wherein the donepezil or the pharmaceutically acceptable salt thereof is donepezil hydrochloride.

28. (New) The method of claim 26, wherein the donepezil is a stereoisomer of formula VII:



VII.

29. (New) The method of claim 26, wherein the donepezil is a stereoisomer of formula VIII:



VIII.

30. (New) The method of claim 26, wherein the therapeutically effective amount is from 1 mg to 100 mg.

31. (New) The method of claim 26, wherein donepezil or the pharmaceutically acceptable salt thereof is orally administered.

32. (New) The method of claim 26, wherein donepezil or the pharmaceutically acceptable salt thereof is orally administered in the form of a tablet.

33. (New) The method of claim 26, wherein donepezil or the pharmaceutically acceptable salt thereof is topically administered.


34. (New) The method of claim 26, wherein donepezil or the pharmaceutically acceptable salt thereof is topically administered in the form of a transdermal patch.

35. (New) A method for treating Parkinson's disease in a patient in need thereof comprising administering a therapeutically effective amount of donepezil or a pharmaceutically acceptable salt thereof.

36. (New) The method of claim 35, wherein the method for treating Parkinson's disease is a method for treating one or more motor dysfunctions caused by Parkinson's disease.


37. (New) The method of claim 35, wherein the donepezil or the pharmaceutically acceptable salt thereof is donepezil hydrochloride.

38. (New) The method of claim 35, wherein the donepezil or the pharmaceutically acceptable salt thereof is a compound of formula VII:



VII.

39. (New) The method of claim 35, wherein the donepezil or the pharmaceutically acceptable salt thereof is a compound of formula VIII:



VIII.

40. (New) The method of claim 35, wherein the therapeutically effective amount is from 1 mg to 100 mg.